DK0876498T3 - Mixing of recombinant vaccinia virus vectors such as polyenv vaccines against HIV - Google Patents

Mixing of recombinant vaccinia virus vectors such as polyenv vaccines against HIV

Info

Publication number: DK0876498T3
Authority: DK; Denmark
Prior art keywords: mixing; vaccinia virus; virus vectors; recombinant vaccinia; against hiv
Prior art date: 1996-01-23

Application number

DK97903823T

Other languages

Danish (da)

Inventor

Julia Hurwitz

Christopher Coleclough

Karen Slobod

Randall Owens

Original Assignee

St Jude Childrens Res Hospital

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-01-23

Filing date

1997-01-23

Publication date

2005-02-07

1997-01-23 Application filed by St Jude Childrens Res Hospital filed Critical St Jude Childrens Res Hospital

2005-02-07 Application granted granted Critical

2005-02-07 Publication of DK0876498T3 publication Critical patent/DK0876498T3/en

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24171—Demonstrated in vivo effect
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Microbiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Zoology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Communicable Diseases (AREA)
Biomedical Technology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

DK97903823T 1996-01-23 1997-01-23 Mixing of recombinant vaccinia virus vectors such as polyenv vaccines against HIV DK0876498T3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/590,288 US5741492A (en)	1996-01-23	1996-01-23	Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
PCT/US1997/000669 WO1997027311A1 (en)	1996-01-23	1997-01-23	Mixture of recombinant vaccinia vectors as polyenv vaccines for hiv

Publications (1)

Publication Number	Publication Date
DK0876498T3 true DK0876498T3 (en)	2005-02-07

Family

ID=24361647

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK97903823T DK0876498T3 (en)	1996-01-23	1997-01-23	Mixing of recombinant vaccinia virus vectors such as polyenv vaccines against HIV

Country Status (29)

Country	Link
US (3)	US5741492A (en)
EP (2)	EP1378516A1 (en)
JP (2)	JP2000504326A (en)
KR (1)	KR100571479B1 (en)
CN (1)	CN1229501C (en)
AP (1)	AP1200A (en)
AT (1)	ATE278790T1 (en)
AU (1)	AU709174B2 (en)
BG (1)	BG64711B1 (en)
BR (1)	BR9707611A (en)
CA (1)	CA2243570C (en)
CZ (1)	CZ296575B6 (en)
DE (1)	DE69731075T2 (en)
DK (1)	DK0876498T3 (en)
EA (1)	EA002390B1 (en)
ES (1)	ES2230596T3 (en)
GE (1)	GEP20032902B (en)
HK (1)	HK1016218A1 (en)
HU (2)	HU224344B1 (en)
IL (2)	IL125497A (en)
NO (1)	NO322261B1 (en)
NZ (1)	NZ331024A (en)
OA (1)	OA10814A (en)
PL (1)	PL188641B1 (en)
PT (1)	PT876498E (en)
RO (1)	RO120268B1 (en)
TR (1)	TR199801418T2 (en)
UA (1)	UA73712C2 (en)
WO (1)	WO1997027311A1 (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7488485B2 (en) *	2003-09-16	2009-02-10	University Of Kansas Medical Center	DNA vaccine compositions and methods of use
GB9711957D0 (en) *	1997-06-09	1997-08-06	Isis Innovation	Methods and reagents for vaccination
US20030138454A1 (en) *	1997-06-09	2003-07-24	Oxxon Pharmaccines, Ltd.	Vaccination method
US6919318B1 (en) *	1998-04-22	2005-07-19	Chiron Corporation	Enhancing immune responses to genetic immunization by using a chemokine
WO1999061049A2 (en) *	1998-05-22	1999-12-02	University Of Massachusetts Medical Center	Model for infection by a pathogen using administration of nucleic acids
US6562800B1 (en) *	1998-10-30	2003-05-13	University Of Southern California	Use of immunopotentiating sequences for inducing immune response
US6759237B1 (en)	1998-11-05	2004-07-06	The Trustees Of The University Of Pennsylvania	Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
WO2000028004A1 (en)	1998-11-10	2000-05-18	The University Of North Carolina At Chapel Hill	Virus vectors and methods of making and administering the same
AU2596600A (en)	1998-12-31	2000-07-31	Chiron Corporation	Modified hiv env polypeptides
US7935805B1 (en)	1998-12-31	2011-05-03	Novartis Vaccines & Diagnostics, Inc	Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
AU2487300A (en)	1998-12-31	2000-07-31	Chiron Corporation	Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US6602705B1 (en) *	1998-12-31	2003-08-05	Chiron Corporation	Expression of HIV polypeptides and production of virus-like particles
ATE300314T1 (en) *	1999-01-28	2005-08-15	Stichting Biomedical Primate R	COMPOSITION AND METHOD FOR IMMUNIZATION AGAINST ONE OR MORE ANTIGENS USING DIFFERENT RECOMBINANT VECTORS
DE19907485B4 (en) *	1999-02-12	2008-01-17	Strathmann Ag & Co.	Virus vaccine
US6420545B1 (en) *	1999-05-24	2002-07-16	The Trustees Of The University Of Pennsylvania	CD4-independent HIV envelope proteins as vaccines and therapeutics
WO2001037878A2 (en) *	1999-11-29	2001-05-31	Orchid Biosciences, Inc.	Methods of identifying optimal drug combinations and compositions thereof
AU1194802A (en)	2000-03-02	2001-12-11	Univ Emory	DNA expression vectors and methods of use
US20040105871A1 (en) *	2000-03-02	2004-06-03	Robinson Harriet L.	Compositions and methods for generating an immune response
US8623379B2 (en) *	2000-03-02	2014-01-07	Emory University	Compositions and methods for generating an immune response
AU2001283094A1 (en) *	2000-08-07	2002-02-18	Sloan-Kettering Institute For Cancer Research	Method and composition for immunization using mixed pools of mutated nucleic acids or peptides
WO2002080982A2 (en) *	2001-01-12	2002-10-17	Chiron Corporation	Nucleic acid mucosal immunization
AU2002252199B2 (en) *	2001-03-08	2008-01-03	Emory University	MVA expressing modified HIV envelope, GAG, and POL genes
WO2003004657A1 (en) *	2001-07-05	2003-01-16	Chiron Corporation	Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
US7211659B2 (en)	2001-07-05	2007-05-01	Chiron Corporation	Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
GB0118532D0 (en) *	2001-07-30	2001-09-19	Isis Innovation	Materials and methods relating to improved vaccination strategies
WO2003020876A2 (en) *	2001-08-31	2003-03-13	Chiron Corporation	Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
US20030170614A1 (en) *	2001-08-31	2003-09-11	Megede Jan Zur	Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US20030228327A1 (en) *	2001-11-05	2003-12-11	Lasher Alfred W.	DNA-based plasmid formulations and vaccines and prophylactics containing the same
US20070269456A1 (en) *	2001-11-05	2007-11-22	Lasher Alfred W	DNA-based plasmid formulations and vaccines and prophylactics containing the same
AU2002347317B2 (en)	2001-11-30	2008-06-26	Isis Innovation Limited	Vaccine
US7094410B2 (en) *	2002-03-02	2006-08-22	The Scripps Research Institute	DNA vaccine against proliferating endothelial cells and methods of use thereof
US6923958B2 (en) *	2002-03-02	2005-08-02	The Scripps Research Institute	DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
US20040106566A1 (en) *	2002-05-17	2004-06-03	Shi-Lung Lin	RNA-splicing and processing-directed gene silencing and the relative applications thereof
DK1523582T3 (en) *	2002-07-18	2009-03-02	Univ Washington	Rapid, efficient purification of HSV-specific T lymphocytes and HSV antigens identified thereby
ES2416629T3 (en) *	2002-12-03	2013-08-02	University Of Massachusetts	Polyvalent primary HIV-1 glycoprotein DNA vaccines and vaccination procedures
US7658927B2 (en) *	2003-05-12	2010-02-09	University Of Florida Research Foundation, Inc.	Materials and methods for immunizing against FIV infection
CN100387301C (en) *	2003-05-12	2008-05-14	佛罗里达大学研究基金公司	Immunization materials and methods against FIV infection
US8076060B2 (en) *	2003-08-04	2011-12-13	Emil William Chynn	Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
AU2004270275B2 (en) *	2003-09-09	2010-02-18	Virxsys Corporation	Lentivirus vector-based approaches for generating an immune response to HIV humans
EP1667631A4 (en) *	2003-09-15	2010-04-14	Novartis Vaccines & Diagnostic	COMBINED APPROACHES TO PRODUCE IMMUNE RESPONSES
WO2005034992A2 (en)	2003-09-15	2005-04-21	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Hiv vaccines based on env of multiple clades of hif
US20050175627A1 (en) *	2003-09-24	2005-08-11	Oxxon Therapeutics Ltd.	HIV pharmaccines
US7622125B2 (en)	2004-05-05	2009-11-24	Novartis Vaccines And Diagnostics, Inc.	Polycistronic HIV vector constructs
CA2568642A1 (en)	2004-05-27	2005-12-15	Centocor, Inc.	Cynomolgus prostate specific antigen
CA2570563A1 (en) *	2004-06-15	2006-09-28	Centocor, Inc.	Method for screening agents against human prostate disease
BRPI0513390A (en) *	2004-07-16	2008-05-06	Us Gov Health & Human Serv	AIDS vaccines containing cmv / r nucleic acid constructs
WO2006044864A2 (en) *	2004-10-19	2006-04-27	Duke University	Vaccine adjuvant
US20100015211A1 (en) *	2004-11-01	2010-01-21	Barnett Susan W	Combination Approaches For Generating Immune Responses
US7892809B2 (en) *	2004-12-15	2011-02-22	The University Of North Carolina At Chapel Hill	Chimeric vectors
WO2008048984A2 (en) *	2006-10-18	2008-04-24	St. Jude Children's Research Hospital	Methods and compositions for preparing a universal influenza vaccine
WO2010093784A2 (en)	2009-02-11	2010-08-19	The University Of North Carolina At Chapel Hill	Modified virus vectors and methods of making and using the same
WO2012070974A1 (en) *	2010-11-22	2012-05-31	Farber Boris Slavinovich	Vaccines with enhanced immunogenicity and methods for the production thereof
EP2670434B1 (en)	2011-01-31	2018-12-26	Tau Bio-Logic Corp.	Treatment of tauopathies
PL2694101T3 (en)	2011-04-06	2017-07-31	Université Paris Descartes	Pharmaceutical compositions for preventing and/or treating an hiv disease in humans
AU2012340035A1 (en)	2011-11-14	2014-04-17	Susan W. Barnett	Immunogenic complexes of polyanionic carbomers and Env polypeptides and methods of manufacture and use thereof
US9833503B2 (en)	2012-02-24	2017-12-05	President And Fellows Of Harvard College	Methods for displaying polypeptides and uses thereof
CA3008542C (en) *	2015-12-15	2020-06-02	Janssen Vaccines & Prevention B.V.	Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
EP3946605A1 (en)	2019-04-05	2022-02-09	Tauc3 Biologics Limited	Anti-tauc3 antibodies and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5198214A (en) *	1983-08-31	1993-03-30	Stolle Research & Development Corporation	Anti-mastitis polyvalent vaccine, method of administration and method for production thereof
NZ217645A (en) *	1985-09-25	1991-11-26	Oncogen	Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations
IL82104A0 (en) *	1986-04-08	1987-10-30	Usa	Recombinant vaccinia virus expressing human retrovirus genes and method for producing htlb-iii envelope proteins
US5169763A (en) *	1986-04-08	1992-12-08	Transgene S.A., Institut Pasteur	Viral vector coding glycoprotein of HIV-1
US5081226A (en) *	1986-12-30	1992-01-14	The United States Of America As Represented By The Department Of Health And Human Services	Synthetic peptides sharing sequence homology with the HIV envelope protein
WO1990012880A1 (en) *	1989-04-18	1990-11-01	Applied Biotechnology, Inc.	Generation of hybrid genes and proteins by virus-mediated recombination
JP3504659B2 (en) *	1991-06-14	2004-03-08	ヴァイロジェネティクスコーポレイション	Immunodeficiency virus recombinant poxvirus vaccine
US5643578A (en) *	1992-03-23	1997-07-01	University Of Massachusetts Medical Center	Immunization by inoculation of DNA transcription unit
JP4050310B2 (en) *	1994-01-27	2008-02-20	ユニバーシティオブマサチューセッツメディカルセンター	Immunization by inoculation with DNA transcription unit
FR2728794B1 (en) *	1994-12-30	1997-03-21	Rhone Merieux	AVIAN RECOMBINANT VACCINE BASED ON AVIAN HERPES VIRUS, PARTICULARLY AGAINST GUMBORO DISEASE

1996
- 1996-01-23 US US08/590,288 patent/US5741492A/en not_active Expired - Lifetime
1997
- 1997-01-23 WO PCT/US1997/000669 patent/WO1997027311A1/en active IP Right Grant
- 1997-01-23 IL IL125497A patent/IL125497A/en not_active IP Right Cessation
- 1997-01-23 DE DE69731075T patent/DE69731075T2/en not_active Expired - Lifetime
- 1997-01-23 PT PT97903823T patent/PT876498E/en unknown
- 1997-01-23 BR BR9707611A patent/BR9707611A/en not_active Application Discontinuation
- 1997-01-23 HU HU9900389A patent/HU224344B1/en not_active IP Right Cessation
- 1997-01-23 PL PL97328193A patent/PL188641B1/en unknown
- 1997-01-23 HU HU0402182A patent/HU0402182D0/en unknown
- 1997-01-23 NZ NZ331024A patent/NZ331024A/en not_active IP Right Cessation
- 1997-01-23 GE GEAP19974458A patent/GEP20032902B/en unknown
- 1997-01-23 EP EP03077363A patent/EP1378516A1/en not_active Ceased
- 1997-01-23 RO RO98-01218A patent/RO120268B1/en unknown
- 1997-01-23 JP JP9526911A patent/JP2000504326A/en active Pending
- 1997-01-23 EA EA199800638A patent/EA002390B1/en not_active IP Right Cessation
- 1997-01-23 ES ES97903823T patent/ES2230596T3/en not_active Expired - Lifetime
- 1997-01-23 TR TR1998/01418T patent/TR199801418T2/en unknown
- 1997-01-23 CA CA002243570A patent/CA2243570C/en not_active Expired - Fee Related
- 1997-01-23 EP EP97903823A patent/EP0876498B1/en not_active Expired - Lifetime
- 1997-01-23 UA UA98084523A patent/UA73712C2/en unknown
- 1997-01-23 KR KR1019980705646A patent/KR100571479B1/en not_active IP Right Cessation
- 1997-01-23 IL IL15691997A patent/IL156919A0/en unknown
- 1997-01-23 AT AT97903823T patent/ATE278790T1/en active
- 1997-01-23 AP APAP/P/1998/001325A patent/AP1200A/en active
- 1997-01-23 DK DK97903823T patent/DK0876498T3/en active
- 1997-01-23 AU AU18299/97A patent/AU709174B2/en not_active Ceased
- 1997-01-23 US US08/788,815 patent/US5846546A/en not_active Expired - Lifetime
- 1997-01-23 CZ CZ0229398A patent/CZ296575B6/en not_active IP Right Cessation
- 1997-01-23 CN CNB971932344A patent/CN1229501C/en not_active Expired - Fee Related
1998
- 1998-07-22 OA OA9800118A patent/OA10814A/en unknown
- 1998-07-22 NO NO19983377A patent/NO322261B1/en not_active IP Right Cessation
- 1998-08-21 BG BG102712A patent/BG64711B1/en unknown
- 1998-09-21 US US09/157,963 patent/US6086891A/en not_active Expired - Lifetime
1999
- 1999-03-24 HK HK99101230A patent/HK1016218A1/en not_active IP Right Cessation
2007
- 2007-07-17 JP JP2007186200A patent/JP2007259870A/en active Pending

Also Published As

Publication number	Publication date
EP0876498B1 (en)	2004-10-06
CZ229398A3 (en)	1998-12-16
IL125497A0 (en)	1999-03-12
JP2000504326A (en)	2000-04-11
DE69731075D1 (en)	2004-11-11
BG102712A (en)	1999-04-30
US6086891A (en)	2000-07-11
CN1214083A (en)	1999-04-14
KR100571479B1 (en)	2007-06-07
PL188641B1 (en)	2005-03-31
JP2007259870A (en)	2007-10-11
EP0876498A1 (en)	1998-11-11
HK1016218A1 (en)	1999-10-29
CN1229501C (en)	2005-11-30
AU1829997A (en)	1997-08-20
TR199801418T2 (en)	1998-10-21
PT876498E (en)	2005-02-28
KR19990081931A (en)	1999-11-15
IL156919A0 (en)	2004-02-08
RO120268B1 (en)	2005-11-30
UA73712C2 (en)	2005-09-15
HU224344B1 (en)	2005-08-29
NO983377D0 (en)	1998-07-22
HUP9900389A2 (en)	1999-06-28
US5846546A (en)	1998-12-08
NZ331024A (en)	2000-02-28
PL328193A1 (en)	1999-01-18
HU0402182D0 (en)	2004-12-28
EP1378516A1 (en)	2004-01-07
AU709174B2 (en)	1999-08-26
DE69731075T2 (en)	2006-03-09
AP1200A (en)	2003-08-29
AP9801325A0 (en)	1998-09-30
NO322261B1 (en)	2006-09-04
BR9707611A (en)	1999-07-27
EA199800638A1 (en)	1999-02-25
ATE278790T1 (en)	2004-10-15
EA002390B1 (en)	2002-04-25
CZ296575B6 (en)	2006-04-12
HUP9900389A3 (en)	2001-06-28
NO983377L (en)	1998-09-23
OA10814A (en)	2003-01-28
ES2230596T3 (en)	2005-05-01
BG64711B1 (en)	2005-12-30
GEP20032902B (en)	2003-02-25
CA2243570C (en)	2001-08-14
IL125497A (en)	2007-07-04
US5741492A (en)	1998-04-21
CA2243570A1 (en)	1997-07-31
WO1997027311A1 (en)	1997-07-31

Publication	Publication Date	Title
DK0876498T3 (en)	2005-02-07	Mixing of recombinant vaccinia virus vectors such as polyenv vaccines against HIV
AU6217798A (en)	1998-08-25	Avian recombinant live vaccine using, as vector, the avian infectious laryngotracheitis virus
DK1021194T3 (en)	2003-09-01	New improved formulation for the treatment of osteoporosis
ID18351A (en)	1998-04-02	AVIAN RECOMMINED LIVING VACCINES, AS VECTORS USING AVIAN LARINGOTRACHEITIS VIRUS
DE69910580D1 (en)	2003-09-25	ANTIGENIC PEPTIDES DERIVED FROM THE TELOMERASE
MA24422A1 (en)	1998-07-01	LIVE RECOMBINANT AVIAN VACCINE USING THE AVIAN INFECTIOUS LARYNGOTRACHAITIS VIRUS AS A VECTOR.
DE69837012D1 (en)	2007-03-22	PREPARATION OF IMPREGENTS FOR PATHOGENIC STATE OF HIV RETROVIRAL INFECTION
ATE275631T1 (en)	2004-09-15	RECOMBINANT VENEZOLAN EQUINE EQUINO CEPHALITIS VIRUS VACCINE
AU3119895A (en)	1996-03-04	Recombinant virus vectors
BR9710913A (en)	1999-08-17	Malaria vaccine composition
DE69230627D1 (en)	2000-03-09	Recombinant avipox virus
DE69943042D1 (en)	2011-01-27	PREPARATION OF DISPERSANT-CONTAINING CONCENTRATES OF HIGH MOLECULAR WEIGHT
EP1392842A4 (en)	2005-01-05	VECTORS OF THE RECOMBINANT VACCINE VIRUS
DE69909866D1 (en)	2003-09-04	Polymerization of hexafluoropropene oxide
ATE348169T1 (en)	2007-01-15	SELECTIVE-REPLICATING VIRAL VECTORS
NO974726D0 (en)	1997-10-13	Glucose-inducible, recombinant, viral vector
ID26951A (en)	2001-02-22	MYCOPLASMA HYOPNEUMONTAE RECOMBINANT VACCINE
ID28968A (en)	2001-07-19	THE FORMED AND STABLE VIRUS RABIES MOVIES, AND THE LIVES OF VACCINES FROM ITS
FI934777A (en)	1993-10-28	MULTIPEL HEPATITIS B VIRUS YTPROTEINER SOM BILDAR PARTIKLAR
CA2332623A1 (en)	2000-01-13	Recombinant herpes viruses for preparing recombinant adeno-associated viruses
DK0915076T3 (en)	2002-04-22	Process for the preparation of trans- (R, R) -actinol
DE69733607D1 (en)	2005-07-28	PREPARATION OF CYCLOALKYLDIARYLPHOSPHINES
AU2775692A (en)	1994-04-12	Recombinant influenza virus vaccine compositions
DK490487A (en)	1988-03-21	Tissue-specific viral vectors based on the lymphoprophic papavirus virus, their preparation and use
IS4868A (en)	1998-10-16	Treatment of dementia-associated infections of the benign amide virus (HIV-1) with benzamide